CN102802664B - 免疫原性组合物 - Google Patents

免疫原性组合物 Download PDF

Info

Publication number
CN102802664B
CN102802664B CN201080064532.1A CN201080064532A CN102802664B CN 102802664 B CN102802664 B CN 102802664B CN 201080064532 A CN201080064532 A CN 201080064532A CN 102802664 B CN102802664 B CN 102802664B
Authority
CN
China
Prior art keywords
compositionss
pcpa
phtd
lys
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080064532.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102802664A (zh
Inventor
S.加利钱
K.哈珀
B.朱蒂奇
M.奥赫斯-奥诺兰汉姆亨
G.莫尔菲尔德
F.奥萨
M-D.萨尔哈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of CN102802664A publication Critical patent/CN102802664A/zh
Application granted granted Critical
Publication of CN102802664B publication Critical patent/CN102802664B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201080064532.1A 2009-12-22 2010-12-20 免疫原性组合物 Expired - Fee Related CN102802664B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US28923609P 2009-12-22 2009-12-22
US61/289236 2009-12-22
US61/289,236 2009-12-22
US32566010P 2010-04-19 2010-04-19
US61/325660 2010-04-19
US61/325,660 2010-04-19
PCT/CA2010/001977 WO2011075823A1 (en) 2009-12-22 2010-12-20 Immunogenic compositions

Publications (2)

Publication Number Publication Date
CN102802664A CN102802664A (zh) 2012-11-28
CN102802664B true CN102802664B (zh) 2017-04-05

Family

ID=44194860

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080064532.1A Expired - Fee Related CN102802664B (zh) 2009-12-22 2010-12-20 免疫原性组合物

Country Status (12)

Country Link
US (1) US20130183350A1 (enExample)
EP (1) EP2515938A4 (enExample)
JP (2) JP5894083B2 (enExample)
KR (1) KR20120107121A (enExample)
CN (1) CN102802664B (enExample)
AR (1) AR079712A1 (enExample)
AU (1) AU2010335970B2 (enExample)
BR (1) BR112012018343A2 (enExample)
CA (1) CA2783955A1 (enExample)
IL (2) IL220576B (enExample)
WO (1) WO2011075823A1 (enExample)
ZA (1) ZA201204628B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2784447A1 (en) 2009-12-22 2011-06-30 Sanofi Pasteur Limited Adjuvanted immunogenic compositions and related methods
CA2819758A1 (en) 2010-12-03 2012-06-07 Sanofi Pasteur Limited Composition for immunization against streptococcus pneumoniae
BR112013029514A2 (pt) 2011-05-17 2019-09-24 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, método de tratar ou impedir uma doença
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
CN104853768B (zh) * 2012-10-17 2019-04-19 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
CA2894903A1 (en) * 2012-12-14 2014-06-19 Sanofi Pasteur, Ltd. Methods for assessing immunogenicity
EP3116537A4 (en) * 2014-03-10 2017-09-13 Sanofi Pasteur Limited Immunogenic compositions
KR101688960B1 (ko) * 2014-06-11 2016-12-23 전남대학교산학협력단 스쿠티카충 백신 조성물
JP2018502927A (ja) * 2015-01-27 2018-02-01 スリーエム イノベイティブ プロパティズ カンパニー マイクロニードルワクチンパッチ用ミョウバン含有コーティング製剤
GB2556002B (en) * 2015-07-07 2020-12-16 Bluewillow Biologics Inc Methods and compositions for nanoemulsion vaccine formulations
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
WO2023034932A1 (en) * 2021-09-02 2023-03-09 Vaxcyte, Inc. Stabilization of adjuvanted vaccine compositions and their use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022298A2 (en) * 2006-08-17 2008-02-21 The Uab Research Foundation Immunogenic pcpa polypeptides and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT58804A (en) * 1988-12-16 1992-03-30 James Cleland Paton Process for producing pneumolysine mutants and pneumococcus vaccines
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
DK1140157T3 (da) * 1998-12-21 2009-06-08 Medimmune Inc Streptococcus pneumoniae-proteiner og immunogene fragmenter til vacciner
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
EP1863529A1 (en) * 2005-03-23 2007-12-12 GlaxoSmithKline Biologicals S.A. Novel composition
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
AU2008280799B2 (en) 2007-07-23 2013-07-11 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
AU2009208299B2 (en) * 2008-02-01 2015-01-22 Sanofi Pasteur Limited Assay for diagnosing streptococcus pneumoniae
BRPI0923649A2 (pt) * 2008-12-24 2016-01-19 Netherlands Vaccine Inst polipeptídeos de pneumolisina (ply) de streptococcus pneumoniae modificados.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022298A2 (en) * 2006-08-17 2008-02-21 The Uab Research Foundation Immunogenic pcpa polypeptides and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis;GLOVER等;《INFECTION AND IMMUNITY》;20080630;第76卷(第6期);2767-2776 *

Also Published As

Publication number Publication date
AU2010335970B2 (en) 2016-11-03
IL242592A (en) 2017-10-31
BR112012018343A2 (pt) 2017-06-27
US20130183350A1 (en) 2013-07-18
AR079712A1 (es) 2012-02-15
KR20120107121A (ko) 2012-09-28
IL220576B (en) 2018-03-29
EP2515938A4 (en) 2013-08-28
JP2013515015A (ja) 2013-05-02
EP2515938A1 (en) 2012-10-31
WO2011075823A1 (en) 2011-06-30
AU2010335970A1 (en) 2012-07-05
CN102802664A (zh) 2012-11-28
JP2016104776A (ja) 2016-06-09
JP5894083B2 (ja) 2016-03-23
ZA201204628B (en) 2013-02-27
CA2783955A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
CN102802664B (zh) 免疫原性组合物
CN102939105B (zh) 免疫原性组合物和相关的方法
ES2704069T3 (es) Vacuna basada en toxinas de Clostridium difficile
US20150044251A1 (en) Stable compositions for immunising against staphylococcus aureus
CN103732750A (zh) 免疫原性组合物
CN105833260A (zh) 针对肺炎链球菌（Streptococcus Pneumoniae）的疫苗和组合物
CN106103469B (zh) 突变型葡萄球菌抗原
US20110236470A1 (en) GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
CN104582722A (zh) 作为疫苗的艰难梭菌多肽
CA2897020A1 (en) Fused antigen vaccines and compositions against streptococcus pneumoniae
TW201731866A (zh) 脂化之肺炎鏈球菌抗原組合物、製備方法及用途
ES2826555T3 (es) Antígenos de Pseudomonas y combinación de antígenos
US20170157233A1 (en) Immunogenic Compositions
CN112384240B (zh) 糖缀合物疫苗
WO2011128892A2 (en) Modified forms of pneumococcal surface immunogenic protein b (psipb)
NZ615328A (en) Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170405

Termination date: 20181220